Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fields
  2. Enrollment increased: 50 → 150 participants
  3. Eligibility criteria expanded, about 44 words
    • Study description expanded, about 7 words
  4. 4 versions Re-verified since May 5, 2026, no change to tracked fieldsv18-v21
  5. Site contact updatedv17
Show 15 earlier versionsHide 15 earlier versions
  1. Site contact updatedv16
  2. 12 versions Re-verified since Apr 26, 2024, no change to tracked fieldsv4-v15
  3. Eligibility criteria shortened, about 4 wordsv3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 31, 2024 to Jan 31, 2024
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To learn if asciminib can help to control CML. The safety and effects of this drug will also be studied.
Trial Details
NCT Number NCT06236724
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Novartis Pharmaceuticals
Conditions
(from sponsor)		 Chronic Myeloid Leukemia
Related terms Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov